The Drug-Induced Respiratory Disease Website

Diazoxide

Pulmonary arterial hypertension

See Montani D, et al. ERJ Open 2023; in press

Montani D, Antigny F, Jutant EM, Chaumais MC, Le Ribeuz H, Grynblat J, Khouri C, Humbert M

Pulmonary hypertension associated with diazoxide: the SUR1 paradox.

ERJ open research 2023 Nov;9; — 2023 Nov

Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J

Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism.

Hormone research in paediatrics 2019;91;25-32 — 2019 — 25-32

Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS

Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

Pediatric cardiology 2017 Aug;38;1247-1250 — 2017 Aug — 1247-1250

Demirel F, Unal S, Çetin II, Esen I, Arasli A

Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide.

Journal of pediatric endocrinology & metabolism : JPEM 2011;24;603-5 — 2011 — 603-5

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

LATEST CHANGELOG

No activity has been recorded yet.